Advertisement
Screener

TECTONIC THERAPEUTIC, INC. (TECX) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

2.8 / 5 stars · 68/120 Roast Me

TECTONIC THERAPEUTIC, INC. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

TECTONIC THERAPEUTIC, INC. (TECX) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$47.53 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Income Statement › Net Income

us-gaap:ProfitLoss · last filed 2026-08-06

  • TECTONIC THERAPEUTIC, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$22.29M.
  • TECTONIC THERAPEUTIC, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$25.24M.
  • TECTONIC THERAPEUTIC, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$19.23M.
  • TECTONIC THERAPEUTIC, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$19.04M.
  • TECTONIC THERAPEUTIC, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2025 was -$74.15M.
  • TECTONIC THERAPEUTIC, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was -$57.98M.
  • TECTONIC THERAPEUTIC, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was -$42.82M.
  • TECTONIC THERAPEUTIC, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was -$105.89M.
Period endNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month as first filedNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month as first filedNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month as first filedNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month as first filed
2026-06-30-$22.29M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
-$47.53M
10-Q · filed 2026-08-06
-$66.75M
derived: sum of 3 quarters · filed 2026-08-06
-$85.79M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31-$25.24M
10-Q · filed 2026-05-07
-$44.47M
derived: sum of 2 quarters · filed 2026-05-07
-$63.50M
derived: sum of 3 quarters · filed 2026-05-07
-$83.49M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31-$19.23M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
-$38.26M
derived: sum of 2 quarters · filed 2026-02-26
-$58.24M
derived: sum of 3 quarters · filed 2026-08-06
-$74.15M
10-K · filed 2026-02-26
2025-09-30-$19.04M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
-$39.02M
derived: sum of 2 quarters · filed 2026-08-06
-$54.92M
10-Q · filed 2025-11-06
-$67.30M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30-$19.98M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
-$35.89M
10-Q · filed 2026-08-06
-$48.26M
derived: sum of 3 quarters · filed 2026-08-06
-$65.98M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31-$15.91M
10-Q · filed 2026-05-07
-$28.28M
derived: sum of 2 quarters · filed 2026-05-07
-$46.00M
derived: sum of 3 quarters · filed 2026-05-07
-$58.67M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31-$12.37M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
-$30.09M
derived: sum of 2 quarters · filed 2026-02-26
-$42.76M
derived: sum of 3 quarters · filed 2026-02-26
-$57.98M
10-K · filed 2026-02-26
2024-09-30-$17.72M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
-$30.39M
derived: sum of 2 quarters · filed 2025-11-06
-$45.61M
10-Q · filed 2025-11-06
-$53.48M
derived: sum of 4 quarters · filed 2025-11-06
2024-06-30-$12.67M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07
-$27.89M
10-Q · filed 2025-08-07
-$35.76M
derived: sum of 3 quarters · filed 2025-08-07
-$45.81M
derived: sum of 4 quarters · filed 2025-08-07
2024-03-31-$15.22M
10-Q · filed 2025-05-08
-$6.81M
10-Q · filed 2024-05-09
-$23.09M
derived: sum of 2 quarters · filed 2025-05-08
-$33.14M
derived: sum of 3 quarters · filed 2025-05-08
-$33.09M
derived: sum of 4 quarters · filed 2025-05-08
2023-12-31-$7.87M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20
-$17.92M
derived: sum of 2 quarters · filed 2025-03-20
-$17.87M
derived: sum of 3 quarters · filed 2025-03-20
-$42.82M
10-K · filed 2025-03-20
$12.16M
10-K · filed 2024-03-14
2023-09-30-$10.05M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12
-$10.00M
derived: sum of 2 quarters · filed 2024-11-12
-$34.95M
10-Q · filed 2024-11-12
$20.94M
10-Q · filed 2023-11-09
-$59.99M
derived: sum of 4 quarters · filed 2024-11-12
2023-06-30$57.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14
-$24.90M
10-Q · filed 2024-08-14
$42.52M
10-Q · filed 2023-08-10
-$49.93M
derived: sum of 3 quarters · filed 2024-08-14
-$72.90M
derived: sum of 4 quarters · filed 2024-08-14
2023-03-31-$24.96M
10-Q · filed 2024-05-09
-$49.99M
derived: sum of 2 quarters · filed 2024-05-09
-$72.96M
derived: sum of 3 quarters · filed 2024-05-09
-$101.01M
derived: sum of 4 quarters · filed 2024-05-09
2022-12-31-$25.03M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14
-$48.00M
derived: sum of 2 quarters · filed 2024-03-14
-$76.06M
derived: sum of 3 quarters · filed 2024-03-14
-$105.89M
10-K · filed 2024-03-14
2022-09-30-$22.97M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09
-$51.02M
derived: sum of 2 quarters · filed 2023-11-09
-$80.86M
10-Q · filed 2023-11-09
-$109.08M
derived: sum of 4 quarters · filed 2023-11-09
2022-06-30-$28.05M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10
-$57.89M
10-Q · filed 2023-08-10
-$86.11M
derived: sum of 3 quarters · filed 2023-08-10
-$118.73M
derived: sum of 4 quarters · filed 2023-08-10
2022-03-31-$29.83M
10-Q · filed 2023-05-11
-$58.06M
derived: sum of 2 quarters · filed 2023-05-11
-$90.67M
derived: sum of 3 quarters · filed 2023-05-11
-$122.06M
derived: sum of 4 quarters · filed 2023-05-11
2021-12-31-$28.23M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23
-$60.84M
derived: sum of 2 quarters · filed 2023-03-23
-$92.23M
derived: sum of 3 quarters · filed 2023-03-23
-$119.13M
10-K · filed 2023-03-23
2021-09-30-$32.61M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08
-$64.00M
derived: sum of 2 quarters · filed 2022-11-08
-$90.90M
10-Q · filed 2022-11-08
-$119.03M
derived: sum of 4 quarters · filed 2022-11-08
2021-06-30-$31.39M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09
-$58.29M
10-Q · filed 2022-08-09
-$86.42M
derived: sum of 3 quarters · filed 2022-08-09
-$123.20M
derived: sum of 4 quarters · filed 2022-08-09
2021-03-31-$26.90M
10-Q · filed 2022-05-10
-$55.03M
derived: sum of 2 quarters · filed 2022-05-10
-$91.81M
derived: sum of 3 quarters · filed 2022-05-10
-$120.64M
derived: sum of 4 quarters · filed 2022-05-10
2020-12-31-$28.13M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17
-$64.91M
derived: sum of 2 quarters · filed 2022-03-17
-$93.74M
derived: sum of 3 quarters · filed 2022-03-17
-$119.71M
10-K · filed 2022-03-17
2020-09-30-$36.78M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04
-$65.61M
derived: sum of 2 quarters · filed 2021-11-04
-$91.58M
10-Q · filed 2021-11-04
-$114.24M
derived: sum of 4 quarters · filed 2021-11-04
2020-06-30-$28.83M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05
-$54.80M
10-Q · filed 2021-08-05
-$77.46M
derived: sum of 3 quarters · filed 2021-08-05
-$94.61M
derived: sum of 4 quarters · filed 2021-08-05
2020-03-31-$25.97M
10-Q · filed 2021-05-13
-$48.63M
derived: sum of 2 quarters · filed 2021-05-13
-$65.78M
derived: sum of 3 quarters · filed 2021-05-13
-$81.83M
derived: sum of 4 quarters · filed 2021-05-13
2019-12-31-$22.66M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18
-$39.81M
derived: sum of 2 quarters · filed 2021-03-18
-$55.86M
derived: sum of 3 quarters · filed 2021-03-18
-$72.97M
10-K · filed 2021-03-18
2019-09-30-$17.14M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05
-$33.20M
derived: sum of 2 quarters · filed 2020-11-05
-$50.30M
10-Q · filed 2020-11-05
-$66.32M
derived: sum of 4 quarters · filed 2020-11-05
2019-06-30-$16.05M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06
-$33.16M
10-Q · filed 2020-08-06
-$49.18M
derived: sum of 3 quarters · filed 2020-08-06
-$60.77M
derived: sum of 4 quarters · filed 2020-08-06
2019-03-31-$17.10M
10-Q · filed 2020-05-07
-$33.12M
derived: sum of 2 quarters · filed 2020-05-07
-$44.72M
derived: sum of 3 quarters · filed 2020-05-07
-$55.22M
derived: sum of 4 quarters · filed 2020-05-07
2018-12-31-$16.02M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16
-$27.61M
derived: sum of 2 quarters · filed 2020-03-16
-$38.12M
derived: sum of 3 quarters · filed 2020-03-16
-$46.36M
10-K · filed 2020-03-16
2018-09-30-$11.59M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07
-$22.10M
derived: sum of 2 quarters · filed 2019-11-07
-$30.34M
10-Q · filed 2019-11-07
-$37.94M
derived: sum of 4 quarters · filed 2019-11-07
2018-06-30-$10.51M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08
-$18.75M
10-Q · filed 2019-08-08
-$26.34M
derived: sum of 3 quarters · filed 2019-08-08
-$32.79M
derived: sum of 4 quarters · filed 2019-08-08
2018-03-31-$8.24M
10-Q · filed 2019-05-13
-$15.84M
derived: sum of 2 quarters · filed 2019-05-13
-$22.28M
derived: sum of 3 quarters · filed 2019-05-13
2017-12-31-$7.60M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-25
-$14.04M
derived: sum of 2 quarters · filed 2019-03-25
-$18.65M
10-K · filed 2019-03-25
2017-09-30-$6.44M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13
-$11.05M
10-Q · filed 2018-11-13
2017-06-30-$4.61M
10-Q · filed 2018-08-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
REGENXBIO Inc. (RGNX)United States$0.477B-3.30
Entera Bio Ltd. (ENTX)$0.485B
Eikon Therapeutics, Inc. (EIKN)United States$0.446B
Kyverna Therapeutics, Inc. (KYTX)United States$0.434B-3.60
Autolus Therapeutics plc (AUTL)$0.506B-1.52
Editas Medicine, Inc. (EDIT)United States$0.424B-4.29
Scribe Therapeutics, Inc. (SCTX)United States$0.410B
Zura Bio Ltd (ZURA)$0.398B-6.56
Surrozen, Inc./DE (SRZN)United States$0.395B
AGENUS INC (AGEN)United States$0.383B1.41